Skip to navigation Skip to content

Gastrointestinal stromal tumour Program in Pharmaceutical Benefits Scheme (PBS) 012-18053000

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised imatinib, ripretinib and sunitinib for patients with gastrointestinal stromal tumour (GIST).

GIST and listing dates

Gastrointestinal stromal tumour is a type of tumour occurring in the gastrointestinal tract, most commonly in the stomach or small intestine.

Listing dates are:

  • imatinib - 1 February 2004 – Metastatic/Unresectable
  • sunitinib - 1 December 2009
  • imatinib - 1 September 2011 – Adjuvant
  • ripretinib - 1 December 2021 – Metastatic/Unresectable

For more information, see Written Authority Required Drugs.

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex Drugs Programs team and choose the option relevant to the condition treated.

The Resources page contains links to application forms, contact details, item and restriction codes, the PBS schedule and the Services Australia websites.

Tier 0 technical support - self-sufficiency

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)

Process telephone Authority approval application

Processing Written Authority requests

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Written Authority Required Drugs